Literature DB >> 20884780

An acoustic study of the relationships among neurologic disease, dysarthria type, and severity of dysarthria.

Yunjung Kim1, Raymond D Kent, Gary Weismer.   

Abstract

PURPOSE: This study examined acoustic predictors of speech intelligibility in speakers with several types of dysarthria secondary to different diseases and conducted classification analysis solely by acoustic measures according to 3 variables (disease, speech severity, and dysarthria type).
METHOD: Speech recordings from 107 speakers with dysarthria due to Parkinson's disease, stroke, traumatic brain injury, and multiple system atrophy were used for acoustic analysis and for perceptual judgment of speech intelligibility. Acoustic analysis included 8 segmental/suprasegmental features: 2nd formant frequency slope, articulation rate, voiceless interval duration, 1st moment analysis for fricatives, vowel space, F0, intensity range, and Pairwise Variability Index.
RESULTS: The results showed that (a) acoustic predictors of speech intelligibility differed slightly across diseases and (b) classification accuracy by dysarthria type was typically worse than by disease type or severity.
CONCLUSIONS: These findings were discussed with respect to (a) the relationship between acoustic characteristics and speech intelligibility and (b) dysarthria classification.

Entities:  

Mesh:

Year:  2010        PMID: 20884780     DOI: 10.1044/1092-4388(2010/10-0020)

Source DB:  PubMed          Journal:  J Speech Lang Hear Res        ISSN: 1092-4388            Impact factor:   2.297


  44 in total

1.  Effect of level of presentation to listeners on scaled speech intelligibility of speakers with dysarthria.

Authors:  Yunjung Kim; Christina Kuo
Journal:  Folia Phoniatr Logop       Date:  2012       Impact factor: 0.849

2.  Longitudinal change in dysarthria associated with Friedreich ataxia: a potential clinical endpoint.

Authors:  Kristin M Rosen; Joanne E Folker; Adam P Vogel; Louise A Corben; Bruce E Murdoch; Martin B Delatycki
Journal:  J Neurol       Date:  2012-06-06       Impact factor: 4.849

3.  Hybridizing conversational and clear speech to investigate the source of increased intelligibility in speakers with Parkinson's disease.

Authors:  Kris Tjaden; Alexander Kain; Jennifer Lam
Journal:  J Speech Lang Hear Res       Date:  2014-08       Impact factor: 2.297

4.  Impact of clear, loud, and slow speech on scaled intelligibility and speech severity in Parkinson's disease and multiple sclerosis.

Authors:  Kris Tjaden; Joan E Sussman; Gregory E Wilding
Journal:  J Speech Lang Hear Res       Date:  2014-06-01       Impact factor: 2.297

5.  Vowel acoustics in dysarthria: speech disorder diagnosis and classification.

Authors:  Kaitlin L Lansford; Julie M Liss
Journal:  J Speech Lang Hear Res       Date:  2014-02       Impact factor: 2.297

6.  Decreased approach behavior and nucleus accumbens immediate early gene expression in response to Parkinsonian ultrasonic vocalizations in rats.

Authors:  Joshua D Pultorak; Cynthia A Kelm-Nelson; Lauren R Holt; Katherine V Blue; Michelle R Ciucci; Aaron M Johnson
Journal:  Soc Neurosci       Date:  2015-09-14       Impact factor: 2.083

7.  Vowel acoustics in Parkinson's disease and multiple sclerosis: comparison of clear, loud, and slow speaking conditions.

Authors:  Kris Tjaden; Jennifer Lam; Greg Wilding
Journal:  J Speech Lang Hear Res       Date:  2013-07-09       Impact factor: 2.297

8.  Clear Speech Variants: An Acoustic Study in Parkinson's Disease.

Authors:  Jennifer Lam; Kris Tjaden
Journal:  J Speech Lang Hear Res       Date:  2016-08-01       Impact factor: 2.297

9.  Data-Driven Classification of Dysarthria Profiles in Children With Cerebral Palsy.

Authors:  Kristen M Allison; Katherine C Hustad
Journal:  J Speech Lang Hear Res       Date:  2018-12-10       Impact factor: 2.297

10.  Measures to Evaluate the Effects of DBS on Speech Production.

Authors:  Gary Weismer; Yana Yunusova; Kate Bunton
Journal:  J Neurolinguistics       Date:  2012-03       Impact factor: 1.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.